Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: A randomised controlled study

Gianpiero Benetti, Mauro Borzio, Giuliano Ramella, Giorgio Bellati, Silvia Fargion, Alberto Colombo, Guido Croce, Carlo Iamoletti, Federico Balzola, Mario Rizzetto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The treatment of patients with hepatitis C virus (HCV) genotype 1 infection remains disappointing. In 1999, we started a multicentre study comparing two regimens of recombinant interferon (IFN) alpha-2b plus ribavirin. Group A (90 patients) received ribavirin plus IFN alpha-2b 5 MU/day for 1 month (induction therapy) followed by IFN alpha-2b 5 MU thrice weekly for 5 months. Group B (85 patients) received ribavirin plus IFN alpha-2b 5 MU thrice weekly for 6 months. Responders in both arms received IFN alpha-2b 3 MU thrice weekly for a further 6 months. A followup evaluation was performed at 18 months. One hundred and seventy-five consecutive treatment-naive patients with HCV genotype 1 infection were enrolled in the study. A sustained virological response (SVR) was obtained in 51 (29%) patients: 28 in group A (31%) and 23 in group B (27%). HCV-RNA clearance was greater at 3 months among patients who received induction therapy (57 vs 39%; p

Original languageEnglish
Pages (from-to)113-118
Number of pages6
JournalInternal and Emergency Medicine
Volume1
Issue number2
DOIs
Publication statusPublished - Jul 2006

Fingerprint

interferon alfa-2b
Ribavirin
Chronic Hepatitis C
Hepacivirus
Genotype
Infection
Interferon-alpha
Therapeutics
Multicenter Studies

Keywords

  • Chronic hepatitis C
  • Cirrhosis
  • Genotype 1
  • Induction therapy

ASJC Scopus subject areas

  • Emergency Medicine
  • Internal Medicine
  • Medicine(all)

Cite this

Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection : A randomised controlled study. / Benetti, Gianpiero; Borzio, Mauro; Ramella, Giuliano; Bellati, Giorgio; Fargion, Silvia; Colombo, Alberto; Croce, Guido; Iamoletti, Carlo; Balzola, Federico; Rizzetto, Mario.

In: Internal and Emergency Medicine, Vol. 1, No. 2, 07.2006, p. 113-118.

Research output: Contribution to journalArticle

Benetti, Gianpiero ; Borzio, Mauro ; Ramella, Giuliano ; Bellati, Giorgio ; Fargion, Silvia ; Colombo, Alberto ; Croce, Guido ; Iamoletti, Carlo ; Balzola, Federico ; Rizzetto, Mario. / Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection : A randomised controlled study. In: Internal and Emergency Medicine. 2006 ; Vol. 1, No. 2. pp. 113-118.
@article{aafe2279dddb4b33b1c5317a81198480,
title = "Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: A randomised controlled study",
abstract = "The treatment of patients with hepatitis C virus (HCV) genotype 1 infection remains disappointing. In 1999, we started a multicentre study comparing two regimens of recombinant interferon (IFN) alpha-2b plus ribavirin. Group A (90 patients) received ribavirin plus IFN alpha-2b 5 MU/day for 1 month (induction therapy) followed by IFN alpha-2b 5 MU thrice weekly for 5 months. Group B (85 patients) received ribavirin plus IFN alpha-2b 5 MU thrice weekly for 6 months. Responders in both arms received IFN alpha-2b 3 MU thrice weekly for a further 6 months. A followup evaluation was performed at 18 months. One hundred and seventy-five consecutive treatment-naive patients with HCV genotype 1 infection were enrolled in the study. A sustained virological response (SVR) was obtained in 51 (29{\%}) patients: 28 in group A (31{\%}) and 23 in group B (27{\%}). HCV-RNA clearance was greater at 3 months among patients who received induction therapy (57 vs 39{\%}; p",
keywords = "Chronic hepatitis C, Cirrhosis, Genotype 1, Induction therapy",
author = "Gianpiero Benetti and Mauro Borzio and Giuliano Ramella and Giorgio Bellati and Silvia Fargion and Alberto Colombo and Guido Croce and Carlo Iamoletti and Federico Balzola and Mario Rizzetto",
year = "2006",
month = "7",
doi = "10.1007/BF02936535",
language = "English",
volume = "1",
pages = "113--118",
journal = "Internal and Emergency Medicine",
issn = "1828-0447",
publisher = "Springer-Verlag Italia s.r.l.",
number = "2",

}

TY - JOUR

T1 - Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection

T2 - A randomised controlled study

AU - Benetti, Gianpiero

AU - Borzio, Mauro

AU - Ramella, Giuliano

AU - Bellati, Giorgio

AU - Fargion, Silvia

AU - Colombo, Alberto

AU - Croce, Guido

AU - Iamoletti, Carlo

AU - Balzola, Federico

AU - Rizzetto, Mario

PY - 2006/7

Y1 - 2006/7

N2 - The treatment of patients with hepatitis C virus (HCV) genotype 1 infection remains disappointing. In 1999, we started a multicentre study comparing two regimens of recombinant interferon (IFN) alpha-2b plus ribavirin. Group A (90 patients) received ribavirin plus IFN alpha-2b 5 MU/day for 1 month (induction therapy) followed by IFN alpha-2b 5 MU thrice weekly for 5 months. Group B (85 patients) received ribavirin plus IFN alpha-2b 5 MU thrice weekly for 6 months. Responders in both arms received IFN alpha-2b 3 MU thrice weekly for a further 6 months. A followup evaluation was performed at 18 months. One hundred and seventy-five consecutive treatment-naive patients with HCV genotype 1 infection were enrolled in the study. A sustained virological response (SVR) was obtained in 51 (29%) patients: 28 in group A (31%) and 23 in group B (27%). HCV-RNA clearance was greater at 3 months among patients who received induction therapy (57 vs 39%; p

AB - The treatment of patients with hepatitis C virus (HCV) genotype 1 infection remains disappointing. In 1999, we started a multicentre study comparing two regimens of recombinant interferon (IFN) alpha-2b plus ribavirin. Group A (90 patients) received ribavirin plus IFN alpha-2b 5 MU/day for 1 month (induction therapy) followed by IFN alpha-2b 5 MU thrice weekly for 5 months. Group B (85 patients) received ribavirin plus IFN alpha-2b 5 MU thrice weekly for 6 months. Responders in both arms received IFN alpha-2b 3 MU thrice weekly for a further 6 months. A followup evaluation was performed at 18 months. One hundred and seventy-five consecutive treatment-naive patients with HCV genotype 1 infection were enrolled in the study. A sustained virological response (SVR) was obtained in 51 (29%) patients: 28 in group A (31%) and 23 in group B (27%). HCV-RNA clearance was greater at 3 months among patients who received induction therapy (57 vs 39%; p

KW - Chronic hepatitis C

KW - Cirrhosis

KW - Genotype 1

KW - Induction therapy

UR - http://www.scopus.com/inward/record.url?scp=39049189884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049189884&partnerID=8YFLogxK

U2 - 10.1007/BF02936535

DO - 10.1007/BF02936535

M3 - Article

C2 - 17111783

AN - SCOPUS:39049189884

VL - 1

SP - 113

EP - 118

JO - Internal and Emergency Medicine

JF - Internal and Emergency Medicine

SN - 1828-0447

IS - 2

ER -